Lung Cancer Therapeutics Market 2018 -2024 | Global Industry Analysis | PBIGP
Added: (Fri Feb 08 2019)
Pressbox (Press Release) -
Lung Cancer Therapeutics Market 2018 -2024 | Global Industry Analysis | PBIGP
A Report On Lung Cancer Therapeutics Market And Its Current And Future Trends
Lung cancer is a type of cancer affecting lungs which are responsible for inhaling oxygen and breathing out carbon dioxide. Lung cancer is characterized by abnormal growth of tumor cells in the lung tissues. Cigarette smoking is the leading cause of lung cancer all over the world. Also passive smoking can also lead to lung cancer. It can be diagnosed by performing biopsy on the lung cells. The common symptoms include persistent cough, weight loss, shortness of breath and chest pain. Lung cancer can be treated by chemotherapy, radiotherapy and surgery.
Request Sample Report : https://precisionbusinessinsights.com/request-sample?product_id=17067
Factors such as increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of Small Cell Lung Cancer Therapeutics Market. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the market growth.
The global diagnostics and therapeutics for lung cancer market is divided into following categories-
1. Drug class
• Chemotherapy
o Taxol
o Navelbine
o Alimta
o Cisplatin
o Camptosar
o Others
• Targeted therapy
o Gilotrif
o Tarceva
o Avastin
o Iressa
o Others
2. Disease type
• Small cell lung cancer
• Non-small cell lung cancer
• Large carcinoid tumor
3. End-users
• Hospitals
• Oncology Clinics
• Ambulatory surgical centers
And lastly, on the basis of geographical regions, the global diagnostics and therapeutics for lung cancer market have five major regions- Europe, Latin America, Asia Pacific, the Middle East and Africa, and North America. North America non-small cell lung cancer market is growing due to increased cases of lung cancer majorly in U.S., increase the funding for the R&D activities, and early diagnosis of the disease is expected to propel the market. In Europe region, increased cases, rise in the government funding for lung cancer R&D activities, and advanced healthcare infrastructure are boosting the non-small cell lung cancer market. Asia Pacific region is exhibiting significant growth in the market owing to rapid industrialization and availability of low-cost generic products in the region.
Some of the key players include Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.), AstraZeneca (U.S.), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Novartis AG (Switzerland), Takeda Pharmaceuticals Co. Ltd. (Japan), Abbvie, Inc. (U.S.), VisionGate, Inc. (U.S.), and Asterias Biotherapeutics (Biotime) (U.S.) to name a few. Some of the market innovations include Takeda Pharmaceutical received an approval from FDA in 2017, Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer.
Global Diagnostics And Therapeutics For Lung Cancer market is growing at a significant rate owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in Small Cell Lung Cancer Therapeutics Market. For instance, in 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer.
For More Information : https://precisionbusinessinsights.com/market-reports/global-lung-cancer-therapeutics-market/